🚨Trade Alert 🚨 ASPI

🚨Trade Alert 🚨 ASPI͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ This little-known NASDAQ company has developed a very critical technology that needs global attention! Greetings Investors, Isotopes… this word may take some of you back to Chemistry 101. It’s a word that could soon position quietly trading NASDAQ company ASP Isotopes, Inc. (ASPI) into becoming a powerful Big Board giant! This may be one of the most pivotal times to have the company on your radar as it’s trading under $1 right now. Many people have no idea what isotopes are and why they are so important. Isotopes are like identical twins or triplets: very similar in most aspects, except for subtle few differences. They are two or more types of atoms of the same chemical element that have same number of protons and electrons (hence the same chemical properties), but slightly different number of neutrons (hence slightly different weight and physical properties). Leaving out the scientific jargon, in nature isotopes are mixed together, just like M&M chocolate candies: same composition, same taste, same size – just different colors. Isotope separation process should sort them out into fraction of exactly the same types. The problem is that the separation process is very challenging and expensive precisely because isotopes are so similar to each other, with only minor weight differences! This is what makes ASPI a critical company to have on your watch list…. Over the past 18 years, ASPI’s scientists have developed the Aerodynamic Separation Process (ASP) that allows for the enrichment of isotopes that either cannot be enriched, or are challenging to enrich, using traditional approaches. Specifically, the company’s technology allows them to enrich elements with both low and high atomic masses. ASPI is not targeting one big industry, but THREE: Medical, Green Energy, and Industrial. AND… there has already been significant interest from potential customers in the technology! The separation of isotopes has been important during the past century, enabling key activities: - Improved medical diagnostic imaging and the treatment of various diseases and cancers. - Generation of green nuclear energy. - Advanced analytical methods for industrial applications. - Geological experiments and radiocarbon dating. - Food irradiation to reduce pathogen/ In the foreseeable future separation of new isotopes may catalyze new exciting breakthroughs such as Quantum computing, Advanced medical therapies and diagnostic procedures, as well as Satellites and space crafts. For an example of how ASPI is already standing out… Quantum Computers are expected to be 1,000x more powerful than today’s conventional computers and to create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics and other industries. Quantum Computing required ultra-pure Si-28 – which is currently not available at any price on commercial scale. Well ASPI could purify natural Si mix of isotopes which may allow for higher performance of Si-based chips! Since the founding of ASPI, the world has changed dramatically, and the need for new isotope enrichers has never been greater. The existing supply chain for established isotopes has always been fragile, and historically, Russia and China have been the largest providers of enriched isotopes. Given the current geopolitical events, many countries and companies are re-evaluating the identity, ownership and location of their suppliers…. These supply-side shocks are occurring at a time when the need for new isotope products has never been greater, and the range of previously unrecognized applications is rising rapidly, all directly or indirectly linked to changing approaches to energy and security. New isotope production will only enable many of the emerging global megatrends such as advanced healthcare, quantum computing, new small, safe nuclear reactors and green nuclear fusion involving Hydrogen. Currently, there are few or no suppliers for many of these highly specialized isotopes which is a big advantage for ASPI and its game-changing technology! ASPI’S goal is to become a leading producer of isotopes for specialist applications and at current levels could represent an enormous value! ASP Isotopes Inc. [( NASDAQ: ASPI Company Overview: ASP Isotopes Inc., a pre-commercial stage advanced materials company that focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASPI’s initial focus is on the production of Molybdenum-100 which it expects to compete with Molybdenum-99, which is currently used to produce technetium-99m, the most frequently used imaging radionuclide. The supply chain is highly complex and plagued by regular supply interruptions, which in turn is associated with serious implications for both hospitals and patients. The Global Mo-99 market is estimated at > $3bn! Nine of the ten nuclear reactors that currently produce Mo-99 globally are expected to cease operations by 2030. Many companies and governments are searching for alternative methods of producing Technetium-99m that does not involve the fission of uranium. This could bode extremely well for ASPI! The company’s technology also makes ASPI ideally situated to resolve the widely anticipated supply shortage of HALEU. This is the fuel that will power the nuclear reactors of the future!Their technology should allow ASPI to construct a HALEU plant at a lower cost and in a shorter timeframe than alternative technologies! Company Highlights: In the last 18 months, ASPI has had some major milestones: - Successfully acquired two incomplete ASP plants in Pretoria, South Africa, and obtained the required licenses from the nuclear regulators, including the Non-proliferation Council of South Africa, to complete construction of the plants and produce commercial product. - Successful completion and cold commissioning of the first manufacturing plant, capable of enriching light isotopes. - Entered into a Memorandum of Understanding (MOU) with a North American customer for the entire offtake of the Company's first light isotope plant. - Continued construction of the second isotope enrichment facility, including procurement of all major long lead items. - Entered into a 25-year supply agreement for up to $27m per annum of highly enriched Molybdenum-100 with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy). - Completion of initial public offering on NASDAQ. Recently ASPI CEO Paul Mann spoke to Proactive after announcing the conclusion of the construction and cold commissioning of a light isotope enrichment facility in Pretoria, South Africa. Mann highlights the importance of isotopes for many of the most promising emerging technologies in realms including quantum computing, healthcare and sustainable energy. Mann has said that future technologies "are not going to work without isotopes!” You can watch the video here: [( Disruption and Shift in Supply: Recent Disruptions in Supply and Forthcoming Re-Balance - Recent geopolitical events mean that purchasers of isotopes are re-evaluating who and where their suppliers are. - Many countries are reliant on suppliers in other countries for isotopes that are essential to everyday life. The global and regional supply/demand for isotopes is at an inflection point. Existing supply chains for established isotopes are fragile with a worsening outlook…. - Almost all (9 out 10) old nuclear reactors that currently produce the global supply of molybdenum-99 are expected to stop production during the next 10 years. - Many countries have a desire to be self-sufficient in isotopes that are essential to everyday life. - Due to its active nuclear program, Russia has been a large producer and exporter of many critical isotopes that many Western countries have become reliant on. Recent geopolitical events have made many countries try to become more self-sufficient, notably with a suddenly strong preference for non-Russian isotopes (and also preferably non-Chinese isotopes). ASPI’s technology is ideally suited for small enrichment facilities that can produce highly specialized isotopes or allow a country to become self-sufficient in a particular isotope! Key 2023 Goals: - Completion of a second, larger isotope enrichment facility, which is capable of enriching kilogram quantities of various isotopes. - Entering into additional customer contracts for the remaining capacity of this second facility. - Starting commercial production and commercial supply of at least two isotopes - Securing the required permits for the construction of additional plants during the 2024 to 2027 timeframe. The company believes this next location will benefit from renewable energy, which is typically very cost-advantaged vs. any global alternative for a long-period supply contract. In Summary… Many emerging global megatrends in new healthcare technologies and advanced quantum computing innovations require a large and reliable supply of specialty isotopes. In addition, it is widely recognized that new suppliers of isotopes will be required for the supply of green energy so that the world can meet longer-term carbon climate goals. ASPI is in dialogue with all the large-scale companies and governmental institutions involved in delivering these global mega-trends! ASPI’s management background includes extensive experience investing in both the healthcare industry and the chemicals processing industry. They immediately recognized the potential value of the company’s technology and were able to acquire the assets. They then raised sufficient capital that would allow the company to advance the construction of its facilities. Only 14 months after incorporation, ASPI became listed on the NASDAQ. And importantly, just 17 months from incorporation, it has commenced operations at its first isotope enrichment production facility. The scale and the commercial opportunities that could be ahead are extremely exciting and ASPI’s technology could deliver unique products to the world. There could be astronomical blue-sky growth ahead so start your research right away! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in ASPI. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding ASPI with a start date of 5/08/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042